RB
Roberts Brian Kenneth
Vice-Président Senior, Développement Clinique
OtherM
内部人交易记录
高级管理人员基于 8 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
Discover the complete record of transactions filed by Roberts Brian Kenneth, Vice-Président Senior, Développement Clinique. Director active across 1 company, notably Rezolute, Inc.. Aggregated, 18 disclosures have been logged. Split: 13 buys · 0 sell. Total volume traded: €193k. Activity tracked since 4 May 2022. The latest transaction was filed on 2 July 2026 (Retenue fiscale). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Roberts Brian Kenneth
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报18 总计
3,062 股@ US$4.990.0039% mcap8.5% 占其流量Common SharesSEC:0000912282-26-000936:0
11,439 股@ US$2.9912.3% 占其流量Common SharesSEC:0000912282-26-000412:0
28,000 股@ US$1.7019.6% 占其流量Common SharesSEC:0000912282-25-001427:0
123,000 股0Common SharesSEC:0000912282-25-001299:0
2,500 股@ US$4.37565.6% 占其流量Common SharesSEC:0000912282-25-000718:0
26,000 股0Common SharesSEC:0000912282-25-000659:0
77,000 股0Common SharesSEC:0000912282-25-000173:0
4,000 股@ US$3.909910.2% 占其流量Common SharesSEC:0000912282-24-000496:0
1,500 股@ US$2.722.6% 占其流量Common SharesSEC:0000912282-24-000461:0
500 股@ US$2.550.8% 占其流量Common SharesSEC:0000912282-24-000331:0
500 股@ US$1.850.6% 占其流量Common SharesSEC:0000912282-24-000268:0
10,000 股@ US$1.8812.0% 占其流量Common SharesSEC:0000912282-24-000270:0
500 股@ US$1.850.6% 占其流量Common SharesSEC:0000912282-24-000236:0
6,000 股@ US$1.696.5% 占其流量Common SharesSEC:0000912282-24-000187:0
7,000 股@ US$1.3065.9% 占其流量Common SharesSEC:0000912282-24-000172:0
5,000 股@ US$1.89996.1% 占其流量Common SharesSEC:0000912282-23-000162:0
1,000 股@ US$3.40651.4% 占其流量Common StockSEC:0001567619-22-011253:0
21,052 股@ US$3.8032.1% 占其流量Common StockSEC:0001567619-22-009701:0
About Roberts Brian Kenneth
ROBERTS BRIAN KENNETH is Senior Vice-President, Clinical Development. He has 18 filings in total, and across the 18 sampled filings the transactions are acquisitions totaling EUR 193327, with no sales, between 2022-05-06 and 2026-07-07. His filings concern Rezolute, Inc., where he is Chief Medical Officer.